Amicus Therapeutics, Inc. (FOLD) Receives Average Recommendation of “Buy” from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $18.58.

A number of equities analysts recently weighed in on FOLD shares. Leerink Swann reissued an “outperform” rating and set a $17.00 price objective (down from $18.00) on shares of Amicus Therapeutics in a report on Saturday, September 16th. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. Goldman Sachs Group restated a “neutral” rating and set a $17.00 price target on shares of Amicus Therapeutics in a research report on Friday, October 6th. Chardan Capital restated a “buy” rating and set a $16.50 price target (down from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Finally, Bank of America raised their price target on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th.

Amicus Therapeutics (NASDAQ FOLD) opened at $15.44 on Friday. The firm has a market capitalization of $2,570.00, a PE ratio of -8.44 and a beta of 1.72. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics has a 1-year low of $5.07 and a 1-year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.33) earnings per share. research analysts anticipate that Amicus Therapeutics will post -1.56 earnings per share for the current year.

In other news, Director Donald J. Hayden, Jr. sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $15.00, for a total value of $300,000.00. Following the completion of the transaction, the director now owns 25,814 shares in the company, valued at approximately $387,210. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total value of $73,550.00. Following the transaction, the insider now owns 69,184 shares of the company’s stock, valued at approximately $1,017,696.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 826,114 shares of company stock valued at $11,791,184. 3.40% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in FOLD. Aperio Group LLC raised its stake in Amicus Therapeutics by 13.5% during the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Amicus Therapeutics by 5.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 592,934 shares of the biopharmaceutical company’s stock valued at $5,971,000 after buying an additional 29,983 shares during the last quarter. Rhumbline Advisers raised its stake in Amicus Therapeutics by 2.0% during the second quarter. Rhumbline Advisers now owns 138,438 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 2,690 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in Amicus Therapeutics during the second quarter valued at $1,057,000. Finally, Legal & General Group Plc raised its stake in Amicus Therapeutics by 1.6% during the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock valued at $558,000 after buying an additional 852 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/05/amicus-therapeutics-inc-fold-receives-average-recommendation-of-buy-from-brokerages.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply